Effect of Vitamin D Supplementation on Cardiometabolic Outcomes in Older Australian Adults—Results from the Randomized Controlled D-Health Trial
Authors:
- Briony L. Duarte RomeroBRBriony L. Duarte Romero
- Bruce K. ArmstrongBABruce K. Armstrong
- Catherine BaxterCBCatherine Baxter
- Dallas R. EnglishDEDallas R. English
- Peter R. EbelingPeter R. Ebeling
- Gunter HartelGHGunter Hartel
- Michael G. KimlinMKMichael G. Kimlin
- Renhua NaRNRenhua Na
- Donald S. A. McLeodDMDonald S. A. McLeod
- Hai PhamHPHai Pham
- Tanya RossTRTanya Ross
- Jolieke C. van der PolsJPJolieke C. van der Pols
Open Access
Abstract
Background/Objectives: Observational studies have found inverse associations between 25-hydroxyvitamin D concentration and risk of hypertension, hypercholesterolemia and type 2 diabetes (T2D). More robust evidence from large-scale randomized controlled trials, however, is limited or inconclusive. Methods: The D-Health Trial (N = 21,315) is a randomized, double-blind, placebo-controlled trial of supplementation with monthly doses of 60,000 international units of oral vitamin D3, conducted in Australians aged 60–84 years. Commencing treatment with anti-hypertensive, lipid-modifying, or anti-diabetic drugs was used as a surrogate for incident hypertension, hypercholesterolemia, and T2D, respectively. Outcomes were ascertained via linkage with the Australian Pharmaceutical Benefits Scheme database. Follow-up began 6 months after randomization; we excluded participants without linked data, and those who were prevalent cases or who died prior to start of follow-up. Flexible parametric survival models were used to estimate the effect of vitamin D supplementation on each outcome. Results: We included 10,964 participants (vitamin D, n = 5456 [49.8%]; placebo, n = 5508 [50.2%]) in the analysis of hypertension, 12,126 participants (vitamin D, n = 6038 [49.8%]; placebo, n = 6088 [50.2%]) in the analysis of hypercholesterolemia, and 17,846 (vitamin D, n = 8931 [50.0%]; placebo, n = 8915 [50.0%]) in the analysis of T2D. Over a median follow-up of 4.6 years, 2672 (24.4%), 2554 (21.1%), and 779 (4.4%) participants developed hypertension, hypercholesterolemia, and T2D, respectively. Vitamin D supplementation had no material effect on the incidence of any of hypertension (HR 1.00; 95% CI 0.93 to 1.08), hypercholesterolemia (HR 1.05; 95% CI 0.97 to 1.13), or T2D (HR 0.97; 95% CI 0.84 to 1.12). Conclusions: Monthly supplements of vitamin D did not alter the incidence of any of the three conditions in older, largely vitamin D-replete Australians.Keywords
Funding Information
- National Health and Medical Research Council (GNT1046681)
- National Health and Medical Research Council (GNT1120682)
- National Health and Medical Research Council (GNT1060183)
- National Health and Medical Research Council (GNT1173346)
- National Health and Medical Research Council (GNT1155413)
- National Health and Medical Research Council (GNT1197958)
- Western Australian State Government in partnership with the Australian Federal Government, through Bioplatforms Australia and the National Collaborative Research Infrastructure Strategy
This publication has 30 references indexed in Scilit:
- The Effect of Vitamin D Supplementation on Lipid Profiles: an Umbrella Review of Meta-AnalysesAdvances in Nutrition, 2023
- Predicting deseasonalised serum 25 hydroxy vitamin D concentrations in the D-Health Trial: An analysis using boosted regression treesContemporary Clinical Trials, 2021
- A randomized placebo-controlled trial of vitamin D supplementation for reduction of mortality and cancer: Statistical analysis plan for the D-Health TrialContemporary Clinical Trials Communications, 2019
- Association between lifestyle risk factors and incident hypertension among middle-aged and older AustraliansPreventive Medicine, 2019
- Potential causal associations of serum 25-hydroxyvitamin D with lipids: a Mendelian randomization approach of the HUNT studyEuropean Journal of Epidemiology, 2018
- Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment StudyJAMA Cardiology, 2017
- Vitamin D Metabolite, 25-Hydroxyvitamin D, Regulates Lipid Metabolism by Inducing Degradation of SREBP/SCAPCell Chemical Biology, 2017
- The D-Health Trial: A randomized trial of vitamin D for prevention of mortality and cancerContemporary Clinical Trials, 2016
- Vitamin D and risk of future hypertension: meta-analysis of 283,537 participantsEuropean Journal of Epidemiology, 2013
- A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012